18 papers in the library · 155 citations · publishing 2019-2026
JAMA Psychiatry July 15, 2026 Brian S. Barnett, Franklin King
This Viewpoint reviews the case of sodium oxybate, a product of gamma-hydroxybutyrate (GHB), to illustrate how psychedelics and other Schedule I substances can proceed through a similar regulatory pathway.
The Primary Care Companion For CNS Disorders June 25, 2026 Franklin King, Juliana Zambrano, Erin Mauney et al.
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...
The Primary Care Companion For CNS Disorders June 23, 2026 Franklin King, Brian S. Barnett, S Trevor Taylor et al.
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...
Psychedelic medicine (New Rochelle, N.Y.) June 1, 2026 Brian S. Barnett, Akhil Anand, Jeremy Weleff et al.
Little is known about the correlates of repeated non-medical lysergic acid diethylamide (LSD) use. Therefore, we aimed to determine the prevalence and correlates of past-year LSD use among people aged 18 years and older in the United States who first used LSD at least 5 years ago. Using data from the 2015-2019 National Survey on Drug Use and Health, we examined the estimated weighted prevalence...
General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation
Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...
Journal of Psychoactive Drugs July 2, 2025 Brian S. Barnett, Miranda Arakelian, Jeremy Weleff et al. 2 citations
This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT. The survey also included items asking respondents to retrospectively self-report...
Cleveland Clinic Journal of Medicine March 1, 2025 Franklin King, Brian S. Barnett, Erin Mauney 11 citations
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...
Journal of Clinical Gastroenterology February 17, 2025 Erin Mauney, Franklin King, Helen Burton-Murray et al. 3 citations
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psychedelic-assisted therapy (PAT), in which serotonergic agents like psilocybin are administered in a psychotherapeutic context, has shown promise for refractory psychiatric disorders, including major depressive disorder and post-traumatic stress...
Journal of psychopharmacology (Oxford, England) 2025 Kabir Nigam, Franklin King, Fernando Espí Forcén 4 citations
Ketamine has recently been shown to be non-inferior to electroconvulsive therapy (ECT), one of psychiatry's most effective treatments for depression. Given the novelty of ketamine as well as its interventional nature, ketamine is currently viewed as an alternative to ECT and as such, considered a third-line agent for treatment-refractory depression. However, available data suggest that ketamine...
The American journal of psychiatry 2025 Sharmin Ghaznavi, Jeremy N Ruskin, Stephen J Haggerty et al.
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Indeed, when substances with therapeutic potential are scrutinized...
The British journal of psychiatry : the journal of mental science October 25, 2024 Kabir Nigam, Franklin King, Fernando Espí Forcén 2 citations
Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strategies for refractory depression. This, combined with data on psychiatric treatment outcome mediators, suggests that earlier intervention with ketamine could improve outcomes for patients suffering from refractory depression.
The Primary Care Companion For CNS Disorders October 15, 2024 Franklin King, Acile Nahlawi, Theodore A Stern
The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...
Psychiatric Annals September 1, 2022 Michael Ljuslin, Kabir Nigam, Roxanne Sholevar et al. 4 citations
In addition to physical symptoms and treatment burden, people affected by serious illness experience psychological, social, and spiritual distress. Medical professionals who care for them, including psychiatrists and other mental health clinicians, attend to these multiple dimensions of suffering with the hope and promise of improving patients' quality of life. Yet anxiety, depression,...
Journal of Psychoactive Drugs August 19, 2021 Brian S. Barnett, Yvan Beaussant, Franklin King et al. 64 citations
Despite resurgent interest in psychedelic-assisted therapy, our insights into psychiatrists' knowledge and opinions about medicinal psychedelic applications are surprisingly narrow. Therefore, we anonymously surveyed psychiatrists attending psychedelic didactic presentations at two national meetings about these issues using a 26-item questionnaire. Response rate was 40.20% (106/264)....
J Palliat Med April 13, 2021 Yvan Beaussant, James A. Tulsky, Benjamin Guérin et al. 34 citations
Background: With support from the Radcliffe Institute for Advanced Study at Harvard University, we convened researchers representing palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies. We aimed to define priorities and envision an agenda for future research on psychedelic-assisted therapies in patients with serious illness. Over two days in...
Focus (Am Psychiatr Publ) June 17, 2020 Franklin King, Rebecca Hammond 13 citations
Although psychedelics initially showed promise in treating anxiety disorders, psychedelics were criminalized and research halted in the early 1970s. A subsequent resurgence of research into psychiatric benefits of psychedelic-assisted psychotherapy in the last 20 years has led to a potential paradigm shift in the treatment of numerous psychiatric disorders, including anxiety disorders. Despite...
Figshare 2020 Brian S. Barnett, Yvan Beaussant, Franklin King et al. 3 citations
A survey instrument used to gauge knowledge and opinions of psychiatrists attending national professional conferences about psychedelics and psychedelic assisted psychotherapies.
General Psychiatry December 1, 2019 Eric Bui, Franklin King, Andrew Melaragno 14 citations
While limited advances have occurred in the past 30 years in the pharmacological management of anxiety and stress-related disorders, novel molecular pathways both within and without the monoamine systems are currently under investigation and offer promising new avenues for more effective future treatments. Enhancing psychotherapy approaches with pharmacological compounds offers the potential to...